PD
DNLI icon

Point72 (DIFC)’s Denali Therapeutics DNLI Stock Holding History

Point72 (DIFC)’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$622 Buy
+43
New +$618 ﹤0.01% 1077
2025
Q1 		– Sell
-7,438
Closed -$152K – 1755
2024
Q4 		$152K Buy
7,438
+7,383
+13,424% +$189K 0.01% 922
2024
Q3 		$1.61K Buy
+55
New +$1.36K ﹤0.01% 1332

Other funds holding DNLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Point72 (DIFC)'s DNLI Position: Q3 2025 in Review

Point72 (DIFC) opened a new position in Denali Therapeutics (DNLI) in Q3 2025: 43 shares worth $622. The stake represents ﹤0.01% of the portfolio and ranks #1077 among its holdings. This is a return to the name: Point72 (DIFC) previously reported a position in DNLI as recently as Q4 2024.

Point72 (DIFC) first reported a position in DNLI in Q3 2024 and has held it in 3 quarters since. The position peaked at $152K in Q4 2024. 240 funds tracked by Wall St. Rank hold DNLI as of Q3 2025.

  • Point72 (DIFC) held 43 shares of Denali Therapeutics worth $622 as of Q3 2025.
  • Denali Therapeutics was a new Point72 (DIFC) position in Q3 2025.
  • Denali Therapeutics made up ﹤0.01% of Point72 (DIFC)'s portfolio in Q3 2025, its #1077 holding.
  • Point72 (DIFC) first reported a position in Denali Therapeutics in Q3 2024 and has held it in 3 quarters since.
  • Point72 (DIFC)'s Denali Therapeutics position peaked at $152K in Q4 2024.
  • 240 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2025.

Based on Point72 (DIFC)'s 13F filing for Q3 2025, filed 14 Nov 2025.